Most Recent
The High Court has settled a 16-year battle between the federal government and Sanofi over alleged excess subsidies it paid after a judge blocked the release of a generic version of blood thinner Plavix, saying its job was not to “resurrect” a dead case.
Medical device maker Bayer has successfully defended a class action over its Essure contraceptive, with a judge finding the evidence fell short of proving the device caused chronic inflammation.
US drug company Allergan is facing a class action on behalf of women implanted with textured breast implants that were recalled after they were linked to a form of non-Hodgkin lymphoma.
Bayer has filed a High Court challenge to a decision that invalidated its patents for blockbuster blood thinner Xarelto, saying it would adversely affect drug research and development.
As it fends off a suit by AstraZeneca seeking to block the sale of a cheaper version of Brilinta, generics maker Pharmacor claims a patent for the heart attack drug should not have been extended.
AI tech company Paige can't patent a tool to provide quality control for analysis of pathology images, with IP Australia finding the invention is merely an “administrative scheme” to automate the role of human pathologists.
US animal drug manufacturer Zoetis has lost its challenge a ruling that chucked out three of its patents for a single-dose vaccine to protect pigs from enzootic pneumonia.
The law firm running a class action against Exactech over allegedly faulty joint implants is facing the "impossible task" of settling the case by January, the "drop dead" deadline for resolving the claim under its US parent company's restructuring.
Swiss pharmaceutical giant Novartis has lost its patent infringement case against Sydney-based generics company Pharmacor over a top-selling heart medication.